Valuation dashboard for Can-Fite BioPharma Ltd. (CANF) with P/E N/A, P/B 0.46, EV/EBITDA 0.05 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19.
Analysis Summary
Can-Fite BioPharma Ltd. reported revenue of $408212 in the most recent fiscal year, growing at a 5-year CAGR of -11.8%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -24.6%, net margin -24.3%.
At the current price of $2.24, CANF has negative trailing earnings (P/E not meaningful) and an ROE of -201.06%. Market capitalisation stands at $3M.
Balance sheet quality for CANF: current ratio of 3.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.46 |
| EV / EBITDA | 0.05 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.00 |
| vs Current Price | -100.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CANF | Can-Fite BioPharma Ltd. | $3M | 0.46 | -201.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.24 |
| Market Cap | $3M |
| Exchange | AMEX |
| Country | IL |
Profitability
| Return on Equity | -201.06% |
| Return on Invested Capital | -145.49% |
| Return on Assets | -103.30% |
| Gross Margin | 100.00% |
| Operating Margin | -2456.79% |
| Net Margin | -2426.67% |
Related companies: BDRX · CLDI · CMND · CNSP · GRI · JAGX · KZIA
Explore sector: Healthcare · Biotechnology
More sections of CANF: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks